Much attention has focused on the growth hormones antagonists from the natural sources for the treatment of prostate cancer are being developed to block the activity of IGFs or to promote the activity of IGFBP-3; these agents may offer additional ways of stimulating apoptosis in malignant cancer cells. Here, IGFBP3 is linked to prostate carcinoma.